A Study of the Effect of Isoproterenol on Red Blood Cell Concentrations of Adenine Nucleotides in a Freely Moving Rat Model In Vivo*

Pollen K. Yeung* and Dena Seto
Pharmacokinetics and Metabolism Laboratory, College of Pharmacy and Department of Medicine, Dalhousie University, Halifax, NS, Canada

Abstract

Previous studies have shown that red blood cell (RBC) concentrations of adenine 5’-triphosphate (ATP) may be a key factor for post exercise effects responsible for cardiovascular protection. To test this concept further, we investigated the effect of isoproterenol on ATP metabolism in RBC using a freely moving rat model in vivo. Sprague Dawley rats were given either isoproterenol (30 mg/kg) or saline by subcutaneous (sc) injection. Blood samples were collected sequentially for up to 6 hours for measurement of adenine nucleotides in the RBC. Hemodynamic recordings were collected throughout the experiment. We have found isoproterenol induced 50% mortality under the experimental condition. It decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP) immediately after the injection by -64 ± 22 and -64 ± 20 mmHg in less than 15 min, and increased HR steadily by +158 ± 59 bpm at the end of the experiment. Isoproterenol also increased RBC concentrations of adenine 5-monophosphate (AMP) from 0.04 ± 0.01 to 0.28 ± 0.23 mM (+500%). The rats died had much greater breakdown of ATP to adenosine 5-monophosphate (AMP) in the RBC than those surviving from the injury (p<0.05 for all the comparison).

Keywords: ATP; Biomarkers; Metabolism; Cardiovascular toxicity; Hemodynamic; Cardiovascular homeostasis; Rats

Introduction

Cardiovascular disease including stroke is the leading cause of death and disability worldwide [1-4] and an enormous economic burden to our societies [1,3,5-7]. Prevention by better diagnosis and drug treatment could provide a huge saving for the health care cost worldwide. Despite advancement in modern cardiovascular medicine, the prevalence of hypertension, ischemic heart disease (IHD) and stroke is still on the rise, and that finding an optimum therapy to slow disease progression remains a therapeutic challenge.

The importance of adenosine and adenosine 5’-triphosphate (ATP) in regulating many biological functions has long been recognized, especially for their effects on the cardiovascular system [8-17]. It is known that adenosine and ATP are key factors in regulation of coronary blood flow [12,18-20], inhibiting platelet aggregation [21], protection of myocardium [17,22-24], neuromodulation [25-32], attenuating tissue necrosis [14,33], ischemic preconditioning [34-39], immunomodulation [40], energy metabolism [16,41-43], and perhaps other functions as well (e.g. pain mediation) which maintain the homeostasis of the cardiovascular system. In respond to ischemia, ATP is broken down to release adenosine. The activity of adenosine is very short lived because it is rapidly taken up by myocardial and endothelial cells, red blood cells (RBC), and also rapidly metabolized to inosine and subsequently to hypoxanthine, adenine, 5-adenosyl homocysteine (SAH), and other adenine nucleotides [8,18,44,45]. In our laboratory, we have been studying the potential of circulatory concentrations of adenosine and ATP, and their metabolites as biomarkers for cardiovascular protection and as targets for anti-ischemia drugs for several years [46-49]. It has been postulated that adenosine and ATP may be used as sensitive biomarkers to quantify myocardial and endothelial ischemia [8,44,50], and for monitoring therapeutic effects of anti-ischemia drugs [46,48,51-53]. More recently, we have shown that exercise improves cardiovascular hemodynamic and increases RBC concentrations of ATP and guanosine 5’-triphosphate (GTP) in a rodent model, particularly in the rats pre-treated with diltiazem (DTZ) [47,54,55], which was not observed in non-exercise rats [49]. The increase of circulatory concentrations of adenosine and ATP could be key factors for exercise preconditioning and a mechanism responsible for cardiovascular protection [17,34,56,57]. In order to study the importance of ATP metabolism in RBC in cardiovascular toxicity, we studied the effect of cardiovascular injury induced by isoproterenol on cardiovascular hemodynamic and RBC concentrations of adenine nucleotides in a freely moving rat model in vivo [58,59].

Materials and Methods

Chemicals

Authentic standards of Purine nucleotides including ATP, adenosine-5’-diphosphate (ADP), AMP, and isoproterenol hydrochloride were purchased from Sigma-Aldrich Chem Co. (St. Louis, MO, USA). Solvents were HPLC grade, and all other chemicals were reagent grade (Fisher Scientific, ON, Canada).

Animal study

The protocol followed the Canadian Council on Animal Care guidelines and was approved by the Dalhousie University Committee on Laboratory Animals. Sprague Dawley rats (SDR) with a carotid artery catheter Weighing between 250 and 320 g were used. They were acclimatized at the Carleton Animal Care Centre with free access to food and water for 48 hours before experiment. During experiment, each rat was kept in a freely moving caging environment with free access to drinking water (Figure 1). In the treatment group (n=10), after an hour settling in the cage, isoproterenol hydrochloride (30 mg/
A Study of the Effect of Isoproterenol on Red Blood Cell Concentrations of Adenine Nucleotides in a Freely Moving Rat Model In Vivo*. Cardiol Pharmacol 2: 102. doi:10.4172/2329-6607.1000102

kg) freshly prepared in normal saline (30 mg/mL) was administered by subcutaneous (sc) injection in the dorsal area of the rat. A separate group receiving normal saline was used as control (n=9). Four blood samples (0.3 mL each) were collected from each rat via an indwelling catheter before isoproterenol (labeled as 0, 0.05, 0.25, and 1 hour), and then 7 more samples after isoproterenol labeled as 1.2, 1.5, 2, 3, 4, 5 and 6 hours. The blood samples were immediately mixed with a "Stopping Solution" for measurement of adenine nucleotides (ATP, ADP and AMP) [47]. Hemodynamic recordings including systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were collected continuously throughout the experiment using a TruWave® disposable pressure transducer (Model PX601, Edwards Lifesciences Canada, Inc., Mississauga, ON, Canada) coupled to a Siemens hemodynamic monitor (Siricust 400) and chart recorder (Siredoc) (Erlangen, FRG) [55]. The RBC samples collected were processed and lysed immediately using an ice cold 10% trichloroacetic acid. The lysate samples were stored at -80°C, and concentrations of ATP and other adenine nucleotides in the RBC were determined by a validated HPLC assay [47]. The rats which still survived at the end of the experiment (>5 hours after isoproterenol) were euthanized by cardiac puncture under general anesthesia with isoflurane.

Data analysis

Areas under the curve of RBC concentrations of ATP and other adenine nucleotides were calculated using trapezoidal method (Prism®-5, Graphpad Software Inc., La Jolla, USA). Maximum (Cmax) and minimum (Cmin) concentrations of adenine nucleotides and hemodynamic variables (SBPmax and min, DBPmax and min, HRmax and min, etc.) were obtained directly from the observed data (Figure 2). Hemodynamic and circulating biomarker variables between the control and isoproterenol treatment groups during the experiment were analyzed by student's paired and unpaired t-test, and differences considered significant when p<0.05. In addition, possible relationships between biomarkers from the group mean data and individual rat data were assessed using Pearson Correlation and linear regression analyses, and considered significant at p<0.05 (Minitab® Inc., Release 15.1, State College, PA, USA).

Results

Under the described experimental condition, isoproterenol induced 50% mortality within 5 hours after administration (p<0.05). It decreased SBP and DBP immediately after the injection (<15 min) by -64 ± 22 and -64 ± 20 mmHg (SBPmin and DBPmin), and increased HR by +158 ± 59 bpm at the end of the experiment (p<0.05). Both SBP and DBP rebounded to pre-treatment (baseline) level after 1-2 hours after injection (i.e. SBPmax and DBPmax) (p<0.05), and then fell again for the remaining of the experiment. There was no rebound from the HR response. In addition, isoproterenol also increased RBC concentrations of ADP and AMP immediately after injection, with corresponding decrease of ATP concentration (Figure 2). Two hours after the isoproterenol injection, RBC concentrations of AMP and ADP increased from 0.043 ± 0.0088 to 0.22 ± 0.19 mM (>400%) and 0.41 ± 0.067 to 0.75 ± 0.33 mM (>80%) (p<0.05 by paired t-test). The decrease of ATP concentration in the RBC immediately after isoproterenol was not statistically significant (1.97 ± 0.24 to 1.74 ± 0.45 mM; p>0.05 by paired t-test).

The rats that died (victims) had greater increase of the AMP and ADP concentrations than those surviving ones (survivors) after isoproterenol (Table 1). However, due to the small number of animal in the study (n=10), the difference found between the victims and survivors was not statistically significant. The same difference would have been

Figure 1: In vivo animal model.

Figure 2: Cardiovascular effects of isoproterenol (30 mg/kg sc) vs control (data are presented as mean ± SEM).

Figure 3: Effect of isoproterenol (30 mg/kg sc) on RBC concentrations of adenine nucleotides (data are presented as mean ± SEM).
significant if a larger sample size (e.g. n=20) was used. There was no significant difference in the RBC concentrations of ATP between the dying and surviving rats before or after isoproterenol (Figure 3), nor any difference in the hemodynamic responses to isoproterenol (SBP, DBP, and HR) between the victims and survivors (Figure 4). The survivors from the insult appeared to have higher baseline blood pressure (SBP and DBP) and lower RBC concentrations of ATP before isoproterenol, but the differences were not statistically significant (Tables 1 and 2).

There were significant correlations between the mean RBC concentrations of ATP and ADP (r=-0.962, p<0.05) and between ATP and AMP (r=-0.957, p<0.05) after isoproterenol in the dying rats, but concentrations of ADP and AMP in the rats treated with isoproterenol but not in the surviving ones or in the control group (without isoproterenol) (Figure 5). There were also significant correlations between RBC concentrations of adenine nucleotides.

**Table 1**: Comparison of RBC concentrations of adenine nucleotides in rats treated with isoproterenol (30 mg/kg sc) and control.

| Biomarker variables | Control (n=9) | Isoproterenol treatment (n=10) | Victims* (n=5) | Survivors* (n=5) |
|---------------------|--------------|-------------------------------|----------------|-----------------|
| ATP AUC(0-1 hr) (mM-hr) | 1.56 ± 0.34* | 1.84 ± 0.27 | 2.01 ± 0.25* | 1.70 ± 0.18 |
| ATP AUC(1-4 hr) (mM-hr) | 4.93 ± 0.97 | 5.19 ± 1.04 | 4.68 ± 0.99 | 5.55 ± 0.95 |
| ATP Cmax (mM) | 2.12 ± 0.44 | 2.29 ± 0.37 | 2.13 ± 0.35 | 2.39 ± 0.36 |
| ATP Cmin (mM) | 1.39 ± 0.27 | 1.46 ± 0.42 | 1.39 ± 0.52 | 1.61 ± 0.34 |
| ADP AUC(0-1 hr) (mM-hr) | 0.42 ± 0.16 | 0.46 ± 0.10 | 0.51 ± 0.10 | 0.41 ± 0.08 |
| ADP AUC(1-4 hr) (mM-hr) | 1.11 ± 0.25 | 1.79 ± 0.64* | 1.88 ± 0.84* | 1.64 ± 0.49* |
| ADP Cmax (mM) | 0.53 ± 0.12 | 0.81 ± 0.30* | 0.94 ± 0.34* | 0.65 ± 0.22 |
| ADP Cmin (mM) | 0.32 ± 0.08 | 0.48 ± 0.25 | 0.63 ± 0.30* | 0.34 ± 0.05 |
| AMP AUC(0-1 hr) (mM-hr) | 0.05 ± 0.03 | 0.05 ± 0.01 | 0.05 ± 0.02 | 0.06 ± 0.01 |
| AMP AUC(1-4 hr) (mM-hr) | 0.14 ± 0.09 | 0.45 ± 0.39* | 0.58 ± 0.52* | 0.34 ± 0.21* |
| AMP Cmax (mM) | 0.08 ± 0.04 | 0.28 ± 0.23* | 0.38 ± 0.26* | 0.16 ± 0.11 |
| AMP Cmin (mM) | 0.04 ± 0.03 | 0.10 ± 0.13 | 0.15 ± 0.17 | 0.04 ± 0.02 |

*Rats died within 5 hrs after isoproterenol*  
*Rats survived longer than 5 hrs after isoproterenol*  
*After isoproterenol for 1 hr for control*  
*Data represent mean ± SD*  
*p<0.05 vs. control (t-test)*  
**p<0.04 vs. victims (t-test)***

**Table 2**: Comparison of hemodynamic effect in rats treated with isoproterenol (30 mg/kg sc) and control.

**Table 3**: Comparison of hemodynamic effect in rats treated with isoproterenol (30 mg/kg sc) and control.

**Discussion**

Isoproterenol is known for many years as a stress agent of the sympathetic system which increases HR, but the effects on BP particularly DBP are highly variable [58,60]. After 50–200 mg/kg dose given once daily by subcutaneous (sc) injection for 2 days to rats, isoproterenol has been shown to induce cardiac hypertrophy, increase serum concentrations of lactate dehydrogenase (LDH), creatine kinase (CK), aspartate aminotransferase (AST), serum cardiac troponin I and
ischemia [8,18,44]. The fact that it happened in the RBC and AMP in the RBC after isoproterenol, which is known to occur in the RBC. The results suggested that ATP was broken down to ADP (10 times) such that a relatively small decrease of ATP concentration attributed to the much higher concentrations of ATP in the RBC (5-)

\[ p<0.05 \]

The increase of ADP and AMP concentrations were significant (\( p<0.05 \)), the decrease of ATP concentrations was not. This was probably due to the rebound and those survived from the insult also had significantly lower blood pressure and elevated HR at the end of the experiment similar to the victims (Figure 4). There was no significant difference in hemodynamic response between the survivors and victims (Table 2).

In addition to the hemodynamic effects, there was also an immediate increase of RBC concentrations of ADP and AMP, with a corresponding decrease of ATP concentrations after the isoproterenol injection (Figure 2). While the increase of ADP and AMP concentrations were significant (\( p<0.05 \)), the decrease of ATP concentrations was not. This was probably attributed to the much higher concentrations of ATP in the RBC (5-10 times) such that a relatively small decrease of ATP concentration can lead to much greater increase of ADP and AMP concentrations in the RBC. The results suggested that ATP was broken down to ADP and AMP in the RBC after isoproterenol, which is known to occur in ischemia [8,18,44]. The fact that it happened in the RBC \textit{in vivo} after isoproterenol injection suggests a unique role of ATP metabolism in RBC for cardiovascular homeostasis. It has been proposed that RBC may serve as oxygen sensor in the cardiovascular system [66,67]. The released adenine nucleotides would help to increase blood supply to the tissue and preserve an optimum balance between oxygen supply and demand, thereby modulating the concentrations of tissue ATP within the cardiovascular system. Such a mechanism would eliminate the requirement for a diverse network of sensing sites throughout the vasculature, and should provide a more efficient means of appropriately matching oxygen supply with demand. It is important to note that while there was no difference in the hemodynamic response between the victims and survivors, the RBC concentrations of AMP was considerably higher in the dying rats (Figure 3). However, due to the small number of rats (\( n=10 \)) used in the pilot experiment, the difference was below significant level (\( p=0.12 \)).

Increasing the number of rats to \( n=20 \) could result in significant difference (\( p=0.024 \)).

To identify more sensitive biomarkers predictive of mortality induced by isoproterenol, individual and group mean data were analyzed by association analyses. There were significant correlations between the mean RBC concentrations of ATP and ADP (\( r=-0.962, p<0.05 \)); and also between ATP and AMP (\( r=-0.957, p<0.05 \)) in the dying rats, but not in the surviving ones (Figure 5), suggesting that more ATP was broken down to ADP and AMP in the dying rats. Analysis of individual rat data supported this thesis although only the regression coefficient (\( \beta \)) between ATP and AMP showed significant difference between the victims and survivors (Table 3). The current study suggests that ATP metabolism in the RBC may be sensitive biomarkers predictive of cardiovascular mortality. We have recently shown that a brief exercise (15 minutes on a treadmill at a speed of 10 m/min) induced a greater post-exercise hypotension in spontaneously hypertensive rats (SHR) compared to SDR. It also decreased ATP concentrations in the RBC during exercise in the SHR as opposed to an increase found in SDR. This could be attributed to a reduced energy reserves in the SHR which could imply SHR may be more vulnerable to ischemia injury [69]. The finding is very encouraging as most of the current cardiac biomarkers are physiological and/or pathological markers specific to cardiac tissues and have limited predictive values for cardiovascular mortality [70-72]. However, further study using larger sample size in SDR and SHR to confirm the role of ATP metabolism in RBC for cardiovascular homeostasis is warranted. Significant correlations between RBC concentrations of ADP and AMP were also observed (Figure 5). However, the relationship was not predictive of mortality and not specific for cardiovascular toxicity (Table 3). In summary, we have shown for the first time isoproterenol acutely induced breakdown of ATP to ADP and AMP in RBC \textit{in vivo}, which may be the rate limiting step for cardiovascular toxicity.

![Table 3: Correlation between RBC concentrations of adenine nucleotides in rats after isoproterenol (30 mg/kg sc).](image-url)

| Biomarker variables | Control (n=9) | Isoproterenol treatment (n=10) | Victims (n=5) | Survivors (n=5) |
|--------------------|--------------|-------------------------------|--------------|----------------|
| ATP vs. AMP r*     | -0.051 ± 0.312**, -0.515 ± 0.421 | -0.717 ± 0.362 | -0.262 ± 0.380 |
| ATP vs. AMPβ       | 0.002 ± 0.032* | -0.202 ± 0.204 | -0.318 ± 0.190 | -0.058 ± 0.115** |
| ATP vs. ADP r      | 0.299 ± 0.306* | -0.277 ± 0.569 | -0.429 ± 0.654 | -0.088 ± 0.456 |
| ATP vs. ADP β      | 0.103 ± 0.117* | -0.294 ± 0.542 | -0.523 ± 0.642 | -0.008 ± 0.194 |
| ADP vs. AMP r      | 0.579 ± 0.260 | 0.787 ± 0.253 | 0.812 ± 0.248 | 0.767 ± 0.285 |
| ADP vs. AMP β      | 0.132 ± 0.124* | 0.392 ± 0.277 | 0.296 ± 0.282 | 0.469 ± 0.278 |

* Rats died within 5 hrs after isoproterenol
** Rats survived longer than 5 hrs after isoproterenol
Correlation coefficient
Regression coefficient
Data represent mean ± SD
\( p<0.05 \) vs. isoproterenol (t-test)
\( p<0.04 \) vs. victims (t-test)
Conclusion

Isoproterenol profoundly altered cardiovascular hemodynamic and induced break down of ATP in the RBC to ADP and AMP particularly in the dying rats. Association between RBC concentrations of ATP with AMP or ADP may be used as sensitive and predictive biomarker for cardiovascular mortality.

Acknowledgement

Supported in part by Canadian Institute of Health Research (CIHR), Nova Scotia Health Research Foundation (NSHRF) and Dalhousie Pharmacy Endowment Foundation.

References

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C (2002) World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106: 1602-1605.
2. Wielgosz A (2001) Living with heart disease: The 2001 Annual Report Card on the Health of Canadians. Can J Cardiol 17: 148-149.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223.
4. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics--2011 Update: A Report from the American Heart Association. Circulation 123: e18-e209.
5. Lacey L, Tabberer M (2005) Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail 7: 677-683.
6. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Fenselau G, et al. (2009) Heart Disease and Stroke Statistics--2009 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21-e181.
7. Ariza MA, Vimalananda VG, Rosenzweig JL (2010) The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocr Metab Disord 11: 1-10.
8. Sollieva A (1986) Cardiovascular effects of adenosine in man: possible clinical implications. Prog Neurobiol 27: 319-349.
9. Otis RA, Pearson JD (1990) Cardiovascular purinoceptors. Physiol Rev 70: 761-845.
10. Ely SW, Berne RM (1992) Protective effects of adenosine in myocardial ischemia. Circulation 85: 893-904.
11. Shioide N, Kato M, Nakayama K, Shinohara K, Kurokawa J, et al. (1998) Effect of adenosine triphosphate on human coronary circulation. Intern Med 37: 818-825.
12. Oxhorn BC, Cheek DJ, Buxton IL (2000) Role of nucleotides and nucleosides in the regulation of cardiac blood flow. AACN Clin Issues 11: 241-251.
13. Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-787.
14. Burnstock G (2002) Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22: 364-373.
15. Moens AL, Claeyss MJ, Timmermans JP, Vrints CJ (2005) Myocardial ischemic reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100: 179-190.
16. Ingwall JS (2009) Energy metabolism in heart failure and remodeling. Cardiovasc Res 81: 412-419.
17. Cohen MV, Downey JM (2008) Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103: 203-215.
18. Berne RM (1980) The role of adenosine in the regulation of coronary blood flow. Circ Res 47: 807-813.
19. Jeremias A, Filardo SD, Whitbourn R, Kershoff RS, Yeung AC, et al. (2000) Effects of intravenous and intracoronary adenosine 5′-triphosphate as compared with adenosine on coronary flow and pressure dynamics. Circulation 101: 318-323.
20. Tune JD, Richmond KN, Gorman MW, Feigl EO (2002) Control of coronary blood flow during exercise. Exp Biol Med (Maywood) 227: 238-250.
21. Gerlach E, Becker BF, Nees S (1987) Formation of adenosine by vascular endothelium: a homeostatic and antimicrobialogenic mechanism? Topic and Perspectives in Adenosine Research 309-320.
22. Ashraf M, Ahmad SM (1993) Ca2+ preconditioning elicits a unique protection against the calcium paradox injury in rat heart. Role of adenosine. Circ Res 74: 360-367.
23. Kitakaze M, Hori M, Morita K, Minamino T, Takashima S, et al. (1994) Infarct size-Limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation 89: 1237-1246.
24. Obata T (2002) Adenosine production and its role in protection against ischemic and reperfusion injury of the myocardium. Nihon Yakurigaku Zasshi 119: 273-279.
25. Deckert J, Gliter CH (1994) Adenosine - An endogenous neuroprotective metabolite and neuromodulator. J Neural Transm Suppl 43: 23-31.
26. Zalewska-Kaszubska J (2002) Neuroprotective mechanisms of adenosine action on CNS neurons. Neuronal Neurochir Pol 36: 329-336.
27. Ribeiro JA, Sebastiao AM, de Mendonca A (2003) Participation of adenosine receptors in neuroprotection. Drug News Perspect 16: 80-86.
28. Burnstock G (2009) Purines and sensory nerves. Hand Exp Pharmacol 333-392.
29. Leonelli M, Torrao AS, Britto LR (2009) Unconventional neurotransmitters, neurodegeneration and neuroprotection. Braz J Med Biol Res 42: 68-75.
30. Ralevic V (2009) Purines as neurotransmitters and neuromodulators in blood vessels. Curr Vasc Pharmacol 7: 3-14.
31. Franco M, Perez-Mendez O, Martinez F (2009) Interaction of intrarenal adenosine and angiotensin II in kidney vascular resistance. Curr Opin Nephrol Hypertens 18: 63-73.
32. Burnstock G (2009) Purinergic signalling: past, present and future. Braz J Med Biol Res 42: 3-8.
33. Cain BS, Meldrum DR, Dinarello CA, Meng X, Banerjee A, et al. (1998) Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion. J Surg Res 76: 117-123.
34. De Jong JW, de Jonge R, Keijzer E, Bradamante S (2000) The role of adenosine in preconditioning. Pharmacol Ther 87: 141-149.
35. Funahashi M (2003) Effects of ischemic preconditioning on myocardial protective on cardiac surgery: possibility of ischemic preconditioning and adenosine administration. Ann Thorac Cardiovasc Surg 9: 307-313.
36. Donato M, Gelpi RJ (2003) Adenosine and cardioprotection during reperfusion-an overview. Mol Cell Biochem 251: 153-159.
37. Das M, Das DK (2008) Molecular mechanism of preconditioning. IUBMB Life 60: 199-203.
38. Reffellmann T, Schwarz ER, Skobel CE, Petek O, Hanrath P (2000) [Ischemic preconditioning. Does this animal experiment phenomenon have clinical relevance?]. Med Klin 95: 559-567.
39. Light PE (1999) Cardiac KATP channels and ischemic preconditioning: current perspectives. Can J Cardiol 15: 1123-1130.
40. McCallion K, Harkin DW, Gardiner KR (2004) Role of adenosine in immunomodulation: review of the literature. Crit Care Med 32: 273-277.
41. Rossi A, Lorette S (1996) Energy metabolism patterns in mammalian myocardium adapted to chronic physiopathological conditions. Cardiovasc Res 31: 163-171.
42. Sommerschild HT, Kirkeboen KA (2000) Adenosine and cardioprotection during ischaemia and reperfusion—an overview. Acta Anaesthesiol Scand 44: 1038-1055.
43. Porkka-Heiskanen T, Kalinchuk A, Alanko L, Urrila A, Stenberg D (2003) Adenosine, energy metabolism, and sleep. ScientificWorldJournal 3: 790-798.
of diltiazem on plasma concentrations of oxypurines and uric acid. Therap Drug Monit 19: 286-291.
46. Yeung P, Dauphinee J, Simonson K, Gouzoules T (2009) RBC concentrations of ATP as potential in vivo biomarkers for cardiovascular safety of anti-hypertensive agents in rats. Clin Pharmacol Ther 95: S70.
47. Yeung P, Ding L, Casley W (2008) HPLC assay with UV detection for determination of RBC purine nucleotides concentrations and application for biomarker study in vivo. J Pharm Biomed Anal 47: 377-382.
48. Klein LC, Yeung KP, Berman JN (2009) Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. Biomarkers 14: 554-559.
49. Yeung P, Dauphinee J, Simonson K, Gouzoules T (2011) Anti-ischemia Drugs have no Effect on the in vivo Metabolism of ATP by RBC in Normotensive Restrained Rats. The Open Drug Metabolism Journal 5: 1-6.
50. DeJong JW (1988) Diagnosis of ischemic heart disease with AMP-catabolites. Myocardial Energy Metabolism Developments in Cardiovascular Medicine 91: 237-244.
51. Yeung PK, Mosher SJ, Macrae DA, Klassen GA (1991) Effect of diltiazem and its metabolites on the uptake of adenosine in blood: An in-vitro investigation. J Pharm Pharmacol 43: 685-689.
52. Yeung PK, Mosher SJ, Li R, Farmer PS, Klassen GA, et al. (1993) Erythrocyte adenosine transport. A rapid screening test for cardiovascular drugs. J Pharmacol Toxicol Methods 30: 163-167.
53. Yeung P, Feng J (1998) Potential surrogate markers for pharmacodynamics of diltiazem: RBC concentrations of adenosine and adenine nucleotides. AAPS Annual Meeting.
54. Yeung P, Howlett J, Schindler C (2008) Effects of diltiazem on RBC concentrations of purine nucleotides in an exercise rat model following multiple doses in vivo. Clin Pharmacol Ther Proceedings of the 2008 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics 83: S47.
55. Yeung PK, Dauphinee J, Gouzoules T, Simonson K, Schindler C (2010) Exercise improves hemodynamic profiles and increases red blood cell concentrations of purine nucleotides in a rodent model. Ther Adv Cardiovasc Dis 4: 341-347.
56. Ferdinandy P, Schulz R, Bader GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
57. Kavazis AN (2009) Exercise preconditioning of the myocardium. Sports Med 39: 923-935.
58. Tiwari R, Mohan M, Kasture S, Maxia A, Ballero M (2009) Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res 23: 1361-1366.
59. Shen YJ, Pan SS, Zhuang T, Wang FJ (2011) Exercise preconditioning initiates late cardioprotection against isoproterenol-induced myocardial injury in rats independent of protein kinase C. J Physiol Sci 61: 13-21.
60. Hoffman BB, Lefkowitz R (1990) Catecholamines and Sympathomimetic Drugs. (2nd edn), In: Gilman A, Rall T, Nies A, Taylor P (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Pergamon Press, Canada.
61. Kubavat JB, Aedaq SM (2009) Role of Sida cordifolia L. leaves on biochemical and antioxidant profile during myocardial injury. J Ethnopharmacol 124: 162-165.
62. Vijaya Padma V, Shyamala Devi CS, Ramkumar KM (2006) Effect of fish oil pretreatment on isoproterenol-induced changes in myocardial membrane phospholipids. Nutrition 22: 1171-1176.
63. Alhunwi HN, Zordoky BN, Hammock BD, El-Kadi AOS (2012) Inhibition of soluble epoxide hydrolase confers cardioprotection against isoproterenol-induced cardiac hypertrophy. Modern Therapeutics 2012: Advances in Physiology, Pharmacology, and Pharmaceutical Sciences, Toronto, Canada, 94.
64. Jimenez SK, Jassal DS, Kardami E, Cattini PA (2011) A single bout of exercise promotes sustained left ventricular function improvement after isoproterenol-induced injury in mice. J Physiol Sci 61: 331-336.
65. Tang Y, Wang M, Le X, Meng J, Huang L, et al. (2011) Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats. Phytomedicine 18: 1024-1030.
66. Ellsworth ML (2000) The red blood cell as an oxygen sensor: what is the evidence? Acta Physiol Scand 168: 551-559.
67. Jensen FB (2009) The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. J Exp Biol 212: 3387-3393.
68. Bergfeld GR, Forrester T (1992) Release of ATP from human erythrocytes in oxygen carriers and regulators of local blood flow. J Physiol Sci 42: 40-47.
69. Yeung P, Dauphinee J, Marcoux T (2012) Effect of acute exercise on cardiovascular hemodynamic and red blood cell concentrations of purine nucleotides in hypertensive compared with normotensive rats. Ther Adv Cardiovasc Dis.
70. Ioannidis JP, Tsoulaki I (2012) Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res 110: 658-662.
71. Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C (2012) High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 33: 579-586.
72. Halim SA, Newby LK, Ohman EM (2012) Biomarkers in cardiovascular clinical trials: past, present, future. Clin Chem 58: 45-53.